Vesugen (Vesugen (Lys-Glu-Asp Vascular Bioregulator))
A short synthetic tripeptide bioregulator from the Khavinson family, targeted at vascular tissue. It is used within the peptide-bioregulator community for vascular health and endothelial support, typically in short repeated courses.
How it works
As a signal peptide (Lys-Glu-Asp), it is proposed to enter cells and regulate gene expression in vascular tissue, supporting endothelial function, vascular tone, and normal vessel-wall maintenance.
Key facts
- Molecular weight: ~390 Da
- Half-life: Short (peptide)
- Bioavailability: Oral (encapsulated) or subcutaneous
- Storage: Room temperature (capsules) or refrigerate (injectable).
Dosing overview
- Typical dose: ~1-2 capsules/day or short injectable courses
- Frequency: Once daily
- Duration: 10-30 day courses
- Route: Oral capsule or subcutaneous
Protocol notes
- Bioregulators are usually taken as short courses (often 10-30 days), repeated a few times per year.
- Oral encapsulated forms are taken once daily on an empty stomach.
- Injectable courses follow a similar short-course, repeatable pattern.
Reported benefits
- Vascular/endothelial support
- Proposed vascular tissue regulation
- Short course-based protocol
- Part of bioregulator longevity systems
Possible side effects
- Limited Western clinical data
- Injection site reactions (injectable)
- Unknown long-term effects
Research
- Peptide bioregulators and vascular tissue (2018): Short peptide bioregulators were reported to influence gene expression and tissue-specific function in Russian research programs.
Compare Vesugen
Research and educational reference only. Not medical advice.